Skip to main content
NEO logo

NeoGenomics, Inc.

NEONASDAQHealthcareDiagnostics & Research

$16.39Today:- (-)1Y +56.84%

As of Oct 22, 2026 close

Market cap
$428.86M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$7.07$20.15
Volume (live)
-
Avg. volume (3M)
2.26M

NeoGenomics (NEO) Income Statement

NeoGenomics reported revenue of $727.33M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 10.1% from $660.57M a year earlier. NeoGenomics posted a net loss of $108.03M, compared with a net loss of $78.73M a year earlier. Gross margin was 43.2% and operating margin -12.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $201.66M, up 11.2% from the same quarter a year earlier.

NeoGenomics Income Statement Analysis

Values in millions USD

Scroll to see more
NeoGenomics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue727.33660.57591.64509.73484.33444.45408.83276.74240.25
Cost of Revenue413.04370.47347.04321.83297.27258.56211.99149.48138.30
Gross Profit314.29290.10244.60187.90187.06185.89196.84127.27101.96
Operating Expenses
Research & Development37.0831.1627.3130.3321.878.238.493.003.64
Selling, General & Administrative331.65310.49313.94277.91283.94191.66175.34114.22113.30
Operating Expenses402.42375.55352.34341.00305.81199.89183.83117.2399.05
Operating Income-88.13-85.45-107.74-153.11-118.75-13.9913.0110.042.90
Other Income/Expense
Interest Income9.0718.43-16.906.083.140.000.000.000.00
Interest Expense3.756.62-6.917.588.227.023.716.235.54
Other Income/Expense-27.46-7.0410.64-4.73103.68-0.06-9.36-6.22-5.55
Income
Income Before Tax-110.27-80.68-97.10-159.34-15.08-14.063.653.82-2.65
Income Tax Expense-2.24-1.95-9.13-15.09-6.73-18.23-4.361.18-2.25
Net Income-108.03-78.73-87.97-144.25-8.354.178.012.64-0.40
Net Income - Continuous Operations-108.03-78.73-87.97-144.25-8.354.178.012.64-0.40
Net Income - Discontinued Operations---------
EBITDA-38.69-1.51-24.07-82.3346.5034.8537.6331.7926.55
EBIT-106.52-74.06-96.65-151.76-6.86----
Depreciation & Amortization33.6933.9072.5832.7753.3541.8930.2721.7322.59
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-----
Diluted EPS-1.00-1.00-1.00-1.00-----
Basic Shares Outstanding128.10126.66125.50124.2223.9921.7220.0918.3115.89
Diluted Shares Outstanding128.10126.66125.50124.2223.9922.3620.7218.3115.89

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About NeoGenomics Financial Statements

What was NeoGenomics's revenue in fiscal 2025?

NeoGenomics reported revenue of $727.33M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 10.1% from $660.57M a year earlier.

Is NeoGenomics profitable?

No. NeoGenomics reported a net loss of $108.03M in fiscal 2025. In fiscal 2024 it lost $78.73M.

What is NeoGenomics's operating margin?

NeoGenomics's operating income was −$88.13M on revenue of $727.33M in fiscal 2025, an operating margin of -12.1%, compared with -12.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition